Methods for diagnosing nasal intestinal type adenocarcinomas

The present invention relates to methods and compositions for the diagnostic and for the treatment of nasal intestinal type adenocarcinomas (ITAC). The inventors used a non-invasive brushing technique, which permits to identify transcriptomic and methylation modifications that are consistent with phenotypic profiles and ITACs natural history. Thus, they identified CACNA1C as a new predictive marker of ITAC. In particular, the invention relates to a method of determining whether a subject has or is at risk of having nasal intestinal type adenocarcinoma (ITAC) comprising determining the expression level of CACNA1C in a sample wherein said expression level indicates whether the subject has or is at risk of having a nasal intestinal type adenocarcinoma (ITAC)

Keywords: Q-PCR, Epigenetics, Transcriptomics, Diagnostic in sinonasal tumors, intestinal type adenocarcinomas (ITACs)
Patent Application number: EP19 306 355.9 on 17/10/2019
Clin Epigenetics 2021 Sep 25 Gallet et al. Integrative genomics analysis of nasal intestinal-type adenocarcinomas demonstrates the major role of CACNA1C and paves the way for a simple diagnostic tool in male woodworkers doi: 10.1186/s13148-021-01122-5.



Business Developper
Pierre MAZOT
Pierre MAZOT
Business Developer
Patent filling date: 2019-10-17

You might also be interested in